ICAM1 and non-small cell lung carcinoma: A significant progression-free survival (PFS) benefit was observed in patients with higher expression of ICAM1 both in NSCLC cohorts (n = 43, with RNA sequencing data: GSE126044, n = 16; GSE135222, n = 27, Samsung Medical Center; Fig. 4e) and two melanoma cohorts (GSE93157, n = 25; Liu et al.26, n = 21; Fig. 4f) (Gide et al.27, n = 41; Supplementary Fig. 14A), although ICAM1 itself was not a good prognosis factor (Supplementary Fig. 14B, C).